MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Xeris Pharmaceuticals Operating Income 2011-2026 | XERS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Xeris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.9 M | -33.6 M | -44 M | -81.9 M | -115 M | -83.5 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.9 M | -115 M | -55.6 M |
Quarterly Operating Income Xeris Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.73 M | 4.48 M | -3.09 M | - | -12.9 M | -8.19 M | -14.2 M | - | -4.91 M | -16 M | -13.3 M | - | -18.8 M | -18.9 M | -29.1 M | - | -24.4 M | -25.8 M | -16.7 M | - | -13.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.73 M | -29.1 M | -13 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-704 M | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Edesa Biotech
EDSA
|
-7.01 M | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Fortress Biotech
FBIO
|
-70.2 M | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.26 | 0.22 % | $ 144 M | USA |
 |
Galapagos NV
GLPG
|
-166 M | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
595 M | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
208 M | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
ImmuCell Corporation
ICCC
|
1.65 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Immuron Limited
IMRN
|
-2.87 M | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
1.51 B | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
-7.95 M | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
-47.4 M | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
164 M | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 104.54 | 2.92 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
-45.9 M | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-112 M | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.43 | -4.03 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
-696 K | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-22.6 M | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.22 | 7.69 % | $ 5.3 M | Israel |
 |
Liquidia Corporation
LQDA
|
-51.4 M | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.08 | 0.74 % | $ 436 M | USA |